Search
Dexamethasone Treatment Options in Texas
A collection of 431 research studies where Dexamethasone is the interventional treatment. These studies are located in the Texas, United States. Dexamethasone is used for conditions such as Multiple Myeloma, Lymphoma and Postoperative Pain.
289 - 300 of 431
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Phase 3 Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery
Completed
To evaluate the safety and efficacy of OTX-DP as a sustained release drug (dexamethasone) depot when placed in the canaliculus of the eyelid for the treatment of post-surgical inflammation and pain in subjects who have undergone cataract extraction with intra-ocular lens implantation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2020
Locations: Texan Eye / Keystone Research, Ltd., Austin, Texas
Conditions: Post Ocular Surgical Inflammation and Pain
Effects of Dry Eye Treatments on the Ocular Surface
Completed
The purpose of this study is to evaluate whether, in people with dry eye syndrome, over the counter artificial tears and the prescription eye drop, dexamethasone, change or effect the eyes response to a low humidity environment.
It is known that irritation from dry eye can be improved by over the counter artificial tears because they wet and lubricate the eyes. The prescription eye drop, dexamethasone, can also improve eye irritation by decreasing the inflammation that develops in dry eye. Thus... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2020
Locations: Baylor College of Medicine, Alkek Eye Center, Houston, Texas
Conditions: Keratoconjunctivitis Sicca, Dry Eye Syndrome
Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma
Completed
The goal of this clinical research study is to find the highest tolerable dose of azacitidine that can be given with vorinostat, gemcitabine, busulfan, and melphalan, with a stem cell transplant, and with or without rituximab. Researchers also want to learn about the safety and level of effectiveness of this combination.
Gender:
ALL
Ages:
Between 15 years and 65 years
Trial Updated:
01/14/2020
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced Cancers, Lymphoma
Liposomal Vincristine Plus Dexamethasone in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Completed
The purpose of this study is to find the highest safe dose and to assess the anti-tumor effect of liposomal vincristine with dexamethasone in patients with relapsed or refractory acute lymphoblastic leukemia (ALL).
Gender:
ALL
Ages:
All
Trial Updated:
12/10/2019
Locations: University of Texas M.D. Anderson Cancer Center, Houston, Texas
Conditions: Acute Lymphoblastic Leukemia
Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype
Terminated
The goal of this clinical research study is to find the highest tolerable dose of lenalidomide that can be given in combination with vorinostat, gemcitabine, busulfan, and melphalan, with a stem cell transplant, and with or without rituximab. Researchers also want to learn about the safety and effectiveness of this combination.
Gender:
ALL
Ages:
Between 15 years and 65 years
Trial Updated:
11/26/2019
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Lymphoma
Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma
Completed
To determine the maximum tolerated dose (MTD), if present, and dose schedule of ACY-1215 (ricolinostat) in combination with pomalidomide and low-dose dexamethasone in patients with relapsed-and-refractory multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/20/2019
Locations: UT Southwestern Medical Center Simmons Comprehensive Cancer Center, Dallas, Texas +1 locations
Conditions: Multiple Myeloma
A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma
Completed
The purpose of Part 1 of the study is to determine the safety of the combination of Siltuximab (CNTO 328) and bortezomib (Velcade). The purpose of Part 2 of the study is to compare the length of progression free survival for those patients given CNTO 328 and bortezomib to those patients given bortezomib alone.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
11/07/2019
Locations: Not set, Dallas, Texas +1 locations
Conditions: Multiple Myeloma
Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma
Completed
The purpose of this study is to compare the safety and efficacy of Lenalidomide plus low dose dexamethasone to that of the combination of melphalan, prednisone and thalidomide.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/07/2019
Locations: University of Texas Medical Branch, Galveston, Texas
Conditions: Multiple Myeloma
A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL
Completed
The main purpose of this study is to evaluate the safety of the study drug known as LY3039478 in combination with dexamethasone in participants with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma (T-ALL/T-LBL).
Gender:
ALL
Ages:
2 years and above
Trial Updated:
08/28/2019
Locations: University of Texas MD Anderson, Houston, Texas
Conditions: T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoblastic Lymphoma
Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Completed
The purpose of this study is to identify a safe and tolerable dose of BMS-906024, either alone or in combination with Dexamethasone in subjects with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma who no longer respond to or have relapsed from standard therapies
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2019
Locations: The University Of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Lymphoblastic Leukemia, Acute T-cell, Precursor T-Cell Lymphoblastic Lymphoma
Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known which regimen of combination chemotherapy is most effective for lymphoblastic lymphoma.
PURPOSE: This randomized phase III trial is studying different regimens of combination chemotherapy to compare how well they work in treating children or adolescents with newly diagnosed stage III or stage IV lymphoblastic lymphoma.
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
07/24/2019
Locations: Texas Tech University Health Sciences Center School of Medicine - Amarillo, Amarillo, Texas +11 locations
Conditions: Lymphoma
Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients
Completed
To explore whether Elotuzumab dose administration over approximately 60 minutes is feasible and safe.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2019
Locations: Texas Oncology, Dallas, Texas +5 locations
Conditions: Multiple Myeloma
289 - 300 of 431